Ying Huang1,2, Brian D Williamson1, Zoe Moodie1, Lindsay N Carpp1, Laurent Chambonneau3, Carlos A DiazGranados4, Peter B Gilbert1,2. 1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 2. Department of Biostatistics, University of Washington, Seattle, Washington, USA. 3. Clinical Sciences, Sanofi Pasteur, Marcy-L'Etoile, France. 4. Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Abstract
BACKGROUND: In the CYD14 (NCT01373281) and CYD15 (NCT01374516) dengue vaccine efficacy trials, month 13 neutralizing antibody (nAb) titers correlated inversely with risk of symptomatic, virologically confirmed dengue (VCD) between month 13 (1 month after final dose) and month 25. We assessed nAb titer as a correlate of instantaneous risk of hospitalized VCD (HVCD), for which participants were continually surveilled for 72 months. METHODS: Using longitudinal nAb titers from the per-protocol immunogenicity subsets, we estimated hazard ratios (HRs) of HVCD by current nAb titer value for 3 correlate/endpoint pairs: average titer across all 4 serotypes/HVCD of any serotype (HVCD-Any), serotype-specific titer/homologous HVCD, and serotype-specific titer/heterologous HVCD. RESULTS: Baseline-seropositive placebo recipients with higher average titer had lower instantaneous risk of HVCD-Any in 2- to 16-year-olds and in 9- to 16-year-olds (HR, 0.26 or 0.15 per 10-fold increase in average titer by 2 methods [95% confidence interval {CI}, .14-.45 and .07-.34, respectively]) pooled across both trials. Results were similar for homologous HVCD. There was evidence suggesting increased HVCD-Any risk in participants with low average titer (1:10 to 1:100) compared to seronegative participants (HR, 1.85 [95% CI, .93-3.68]). CONCLUSIONS: Natural infection-induced nAbs were inversely associated with hospitalized dengue, upon exceeding a relatively low threshold.
BACKGROUND: In the CYD14 (NCT01373281) and CYD15 (NCT01374516) dengue vaccine efficacy trials, month 13 neutralizing antibody (nAb) titers correlated inversely with risk of symptomatic, virologically confirmed dengue (VCD) between month 13 (1 month after final dose) and month 25. We assessed nAb titer as a correlate of instantaneous risk of hospitalized VCD (HVCD), for which participants were continually surveilled for 72 months. METHODS: Using longitudinal nAb titers from the per-protocol immunogenicity subsets, we estimated hazard ratios (HRs) of HVCD by current nAb titer value for 3 correlate/endpoint pairs: average titer across all 4 serotypes/HVCD of any serotype (HVCD-Any), serotype-specific titer/homologous HVCD, and serotype-specific titer/heterologous HVCD. RESULTS: Baseline-seropositive placebo recipients with higher average titer had lower instantaneous risk of HVCD-Any in 2- to 16-year-olds and in 9- to 16-year-olds (HR, 0.26 or 0.15 per 10-fold increase in average titer by 2 methods [95% confidence interval {CI}, .14-.45 and .07-.34, respectively]) pooled across both trials. Results were similar for homologous HVCD. There was evidence suggesting increased HVCD-Any risk in participants with low average titer (1:10 to 1:100) compared to seronegative participants (HR, 1.85 [95% CI, .93-3.68]). CONCLUSIONS: Natural infection-induced nAbs were inversely associated with hospitalized dengue, upon exceeding a relatively low threshold.
Authors: Luis Villar; Gustavo Horacio Dayan; José Luis Arredondo-García; Doris Maribel Rivera; Rivaldo Cunha; Carmen Deseda; Humberto Reynales; Maria Selma Costa; Javier Osvaldo Morales-Ramírez; Gabriel Carrasquilla; Luis Carlos Rey; Reynaldo Dietze; Kleber Luz; Enrique Rivas; Maria Consuelo Miranda Montoya; Margarita Cortés Supelano; Betzana Zambrano; Edith Langevin; Mark Boaz; Nadia Tornieporth; Melanie Saville; Fernando Noriega Journal: N Engl J Med Date: 2014-11-03 Impact factor: 91.245
Authors: Leah C Katzelnick; Judith M Fonville; Gregory D Gromowski; Jose Bustos Arriaga; Angela Green; Sarah L James; Louis Lau; Magelda Montoya; Chunling Wang; Laura A VanBlargan; Colin A Russell; Hlaing Myat Thu; Theodore C Pierson; Philippe Buchy; John G Aaskov; Jorge L Muñoz-Jordán; Nikos Vasilakis; Robert V Gibbons; Robert B Tesh; Albert D M E Osterhaus; Ron A M Fouchier; Anna Durbin; Cameron P Simmons; Edward C Holmes; Eva Harris; Stephen S Whitehead; Derek J Smith Journal: Science Date: 2015-09-18 Impact factor: 47.728
Authors: Maria Rosario Capeding; Ngoc Huu Tran; Sri Rezeki S Hadinegoro; Hussain Imam H J Muhammad Ismail; Tawee Chotpitayasunondh; Mary Noreen Chua; Chan Quang Luong; Kusnandi Rusmil; Dewa Nyoman Wirawan; Revathy Nallusamy; Punnee Pitisuttithum; Usa Thisyakorn; In-Kyu Yoon; Diane van der Vliet; Edith Langevin; Thelma Laot; Yanee Hutagalung; Carina Frago; Mark Boaz; T Anh Wartel; Nadia G Tornieporth; Melanie Saville; Alain Bouckenooghe Journal: Lancet Date: 2014-07-10 Impact factor: 79.321
Authors: N Sangkawibha; S Rojanasuphot; S Ahandrik; S Viriyapongse; S Jatanasen; V Salitul; B Phanthumachinda; S B Halstead Journal: Am J Epidemiol Date: 1984-11 Impact factor: 4.897
Authors: Leah C Katzelnick; Lionel Gresh; M Elizabeth Halloran; Juan Carlos Mercado; Guillermina Kuan; Aubree Gordon; Angel Balmaseda; Eva Harris Journal: Science Date: 2017-11-02 Impact factor: 47.728
Authors: Oliver J Brady; Peter W Gething; Samir Bhatt; Jane P Messina; John S Brownstein; Anne G Hoen; Catherine L Moyes; Andrew W Farlow; Thomas W Scott; Simon I Hay Journal: PLoS Negl Trop Dis Date: 2012-08-07
Authors: Tatyana M Timiryasova; Matthew I Bonaparte; Ping Luo; Rebecca Zedar; Branda T Hu; Stephen W Hildreth Journal: Am J Trop Med Hyg Date: 2013-03-04 Impact factor: 2.345